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Abstract
Introduction: Previous in vivo and in vitro studies have shown that melatonin changes vasopressin (AVP) and oxytocin (OT) secretion 
from the rat neurohypophysis. Additionally, melatonin is known to inhibit the forskolin-induced (forskolin is a strong adenylyl cyclase - 
AC activator) increase in cAMP accumulation in the rat pituitary. To determine whether the possible response of vasopressinergic and/or 
oxytocinergic neurones to melatonin could be mediated through a cAMP-dependent mechanism, the effect of different concentrations of 
melatonin (i.e. 10-11, 10-9, 10-7, 10-5 and 10-3 M) on forskolin-stimulated AVP and OT release from the rat hypothalamo-neurohypophysial 
(H-NH) system was studied in vitro.
Materials and methods: Male rats served as donors of the H-NH explants, which were placed in 1 mLof normal Krebs-Ringer fluid 
(nKRF), heated to 37oC and constantly gassed with carbogen (95% O2 and 5% CO2). The H-NH explants were incubated successively in 
nKRF {fluid B1} and incubation fluid as B1 enriched with an appropriate concentration of melatonin, i.e. 10-11 – 10-3 M and/or forskolin 
(at a concentration of 10-5 M) or their vehicles (0.1% ethanol or DMSO) {fluid B2}. After 20 min incubation in fluid B1 and next B2, the 
media were collected and immediately frozen before AVP and OT estimation by the RIA. The AVP and OT secretion was determined by 
using B2/B1 ratio for each H-NH explant.
Results: We have demonstrated that the highly effective AC activator — forskolin significantly stimulated both AVP and OT release from 
isolated rat H-NH system. Such an effect of forskolin was reduced by melatonin at concentrations of 10-9, 10-7 and 10-5 M. The strongest 
effect was exerted by this hormone at a concentration of 10-7 M, which inhibited not only forskolin-stimulated, but also basal, AVP and 
OT release. On the contrary, the highest studied concentration (i.e. 10-3 M) of melatonin stimulated both AVP and OT basal release, but 
when forskolin was present in the medium melatonin at such a concentration remained inactive in modifying these hormones release 
from the H-NH system in vitro.
Conclusions: Our present results demonstrate that in the male rat: 
1. The influence of melatonin on the vasopressinergic and oxytocinergic neurones activity is mediated partly through a cAMP-dependent 
mechanism.
2. The effect of melatonin in this respect depends on its concentration. (Endokrynol Pol 2014; 65 (2): 125–131)
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Streszczenie
Wstęp: Wcześniejsze badania wykazały, że melatonina modyfikuje proces uwalniania wazopresyny (AVP) i oksytocyny (OT) zarówno in 
vivo, jak in vitro. Ponadto stwierdzono, że melatonina hamuje indukowaną forskoliną (forskolina jest silnym aktywatorem cyklazy ade-
nylanowej, której pobudzenie zwiększa syntezę cAMP) akumulację cAMP w przysadce szczura. Aby określić czy cAMP pośredniczy we 
wpływie melatoniny na czynność wydzielniczą neuronów wazopresynergicznych i/lub oksytocynergicznych zbadano wpływ różnych 
stężeń tego hormonu (tj. 10-11, 10-9, 10-7, 10-5, 10-3 M) na wywołane stosowaniem forskoliny uwalnianie AVP i OT z układu podwzgórze - 
część nerwowa przysadki (H-NH) szczura in vitro.
Materiał i metody: Po wyosobnieniu z mózgu, układ H-NH umieszczano w probówkach zawierających 1 mL płynu Krebsa-Ringera 
(K-R) ogrzanego do temperatury 37oC oraz nasycanego mieszaniną karbogen (95% O2 i 5% CO2). Po okresie równoważenia, do probówek 
dodawano normalny płyn K-R {płyn B1}, a następnie płyn B1 zawierający dodatkowo rozpuszczalnik melatoniny (0.1% etanol) lub jej 
roztwór w odpowiednim stężeniu, tj. 10-11 – 10-3 M i/lub forskolinę (w stężeniu 10-5 M), bądź jej rozpuszczalnik (0,1% DMSO) {płyn B2}. 
Po inkubacji układu H-NH w każdym z roztworów (B1 i B2) przez 20 min płyn inkubacyjny pobierano i natychmiast zamrażano do czasu 
oznaczenia w zebranych próbkach zawartości AVP i OT metodą RIA. Stopień uwalniania AVP i OT z układu H-NH in vitro wyrażano 
jako stosunek B2/B1.
Wyniki: Wykazano, że forskolina istotnie zwiększa uwalnianie AVP i OT z układu H-NH do płynu inkubacyjnego in vitro, natomiast 
melatonina (w stężeniach 10-9, 10-7 i 10-5 M) efekt ten istotnie ogranicza. Najsilniejszy efekt hamujący melatonina wywiera w stężeniu 10-7 
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M, hamując nie tylko pobudzane forskoliną, ale także podstawowe uwalnianie obydwu neurohormonów. Przeciwnie, w stężeniu 10-3 M 
melatonina istotnie nasila wydzielanie AVP i OT do płynu inkubacyjnego, natomiast nie zmienia pobudzanego stosowaniem forskoliny 
ich uwalniania.
Wnioski: Wyniki tych badań sugerują, że: 
1. W mechanizmie wpływu melatoniny na sekrecyjną aktywność neuronów wazopresynergicznych i oksytocynergicznych u szczura 
ma znaczenie cAMP.
2. Efekt ten zależy od stężenia melatoniny. (Endokrynol Pol 2014; 65 (2): 125–131)
Słowa kluczowe: wazopresyna; oksytocyna; forskolina; melatonina
This work has been supported by the Medical University of Lodz, contract No. 502-03/6-103-01/502-64-013.
only during the day [12]. When Syrian hamsters were 
used as donors of the tissue, the inhibitory effect of 
melatonin on AVP and OT secretion from the neu-
rointermediate lobe was also noted [13]. Since me-
latonin has been shown to have either a stimulatory 
or an inhibitory influence, or to be without effect on 
AVP or OT secretion from isolated hypothalamus or 
neurointermediate lobe, the primary purpose of the 
present study was, therefore, to investigate whether 
melatonin affects the in vitro release of AVP and OT 
from isolated rat hypothalamo-neurohypophysial 
system in a dose-dependent manner. This is the first 
time this has been investigated.
The intracellular mechanism of melatonin action 
involves the inhibition of calcium influx and calcium 
mobilisation from intracellular stores, as well as the 
inhibition of an adenylyl cyclase (AC)-dependent rise 
in cyclic adenosine monophosphate (cAMP) produc-
tion [14–16]. Melatonin has been shown to inhibit the 
forskolin-induced (forskolin is a strong AC activator) 
increase in cAMP accumulation in the rat pituitary 
[14–15]. Moreover, forskolin has been found to elicit 
an increase in cAMP accumulation in the rat hypotha-
lamic SON and in the neural lobe of the pituitary in 
vitro [17] and cAMP-dependent stimulation of AVP and 
OT release from the posterior pituitary has also been 
described [18]. 
The second purpose of the present study was, there-
fore, to investigate whether the forskolin-stimulated 
secretion of AVP and OT from the rat hypothalamo-
neurohypophysial system in vitro could be modified 
by melatonin and whether such an effect depends 
on a concentration of the hormone in the incubatory 
medium.
Material and methods
Animals
Three-months old male Wistar rats (weighing about 
220–350 g), maintained in a light:dark cycle 12L:12D 
(lights on from 6 a.m.), at a constant temperature 
(+22°C), with standard pelleted food and water avail-
able ad libitum, were used for the experiments.
Introduction
Melatonin, discovered as a hormone produced by the 
pineal hormone, is now well known to be synthesised 
in various organs and tissues. One of the richest sources 
of melatonin in the organism is the gastrointestinal tract 
(GIT), which produces several hundred times more 
melatonin than the pineal gland, and where melatonin 
demonstrates several advantageous, but rather local, 
effects (e.g. gastroprotective and liver-protective ac-
tions) under the conditions of health and disease [1–3]. 
Produced by the pineal gland, melatonin is released 
into the general circulation as well as directly into the 
cerebrospinal fluid, and influences the function of nu-
merous structures in the central nervous system [4–5] 
and the pituitary, both anterior [6–7] and posterior [8] 
part of the gland.
Melatonin has been shown to influence the activ-
ity of hypothalamic supraoptic (SON) and paraven-
tricular (PVN) nuclei and modify vasopressin (AVP) 
and oxytocin (OT) synthesis and release under dif-
ferent experimental conditions, both in vivo and in 
vitro. However, data is not consistent and shows that 
the effect of melatonin on AVP or OT release from the 
hypothalamus and/or neurohypophysis depends on 
the concentration of the hormone, the time of day, 
and the species of animal used as donors of a tissue 
for the in vitro studies [8]. As early as 1979, melatonin 
was reported to stimulate AVP secretion from the rat 
neurohypophysis in a dose-dependent manner [9]. 
Later in vitro studies have shown that this hormone 
was able to stimulate the release of both AVP and OT 
from isolated neurointermediate lobe of sham-op-
erated (i.e. not pinealectomised) or pinealectomised 
rats when used at relatively high concentrations 
(10-6 M and 10-3 M), but at a concentration of 10-7 M 
it was ineffective [10]. In contrast to these observa-
tions, Yasin et al. [11] showed that melatonin had an 
inhibitory effect on both AVP and OT release from 
isolated rat hypothalamus, with maximal inhibition 
at 10-7 M. In addition, the effect of melatonin on the 
neurohypophysial hormones secretion was found 
to depend on the light:dark cycle and could be seen 
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Drugs
Melatonin (N-acetyl-5-methoxytryptamine), forskolin 
and dimethyl sulfoxide (DMSO) were obtained from 
Sigma-Aldrich Chemie GmbH. The AVP (Vasopressin 
synth.) and OT (Oxytocin synth.), for standard curve 
preparation as well as for iodination with 125I, were 
from Peninsula Laboratories Europe Ltd. The anti-AVP 
and anti-OT antibodies were raised by dr hab. Monika 
Orłowska-Majdak (Department of Experimental Physi-
ology, Chair of Experimental and Clinical Physiology, 
Medical University of Lodz).
Experimental procedure in vitro
On the day of the experiment, the animals were decapi-
tated between 9:30 and 10:30 a.m. The brain together 
with the pituitary was carefully removed from the skull, 
and a block of tissue containing the hypothalamus was 
isolated as previously described [19]. After dissection, 
the hypothalamo-neurohypophysial (H-NH) explant 
was placed in a polypropylene tube with 1 mL of nor-
mal Krebs-Ringer fluid (nKRF) heated in a water bath 
to 37°C and constantly gassed with carbogen (95% O2 
and 5% CO2). The nKRF contained: 120 mM NaCl, 5 mM 
KCl, 2.6 mM CaCl2, 1.2 mM KH2PO4, 0.7 mM MgSO4, 
22.5 mM NaHCO3, 10 mM glucose, 1.0 g/L bovine se-
rum albumin and 0.1 g/L ascorbic acid (pH = 7.4–7.5, 
osmolality within the range 285–295 mOsm/kg). At the 
beginning of the experiment, the H-NH explants were 
equilibrated in 1 mL of nKRF (2 × 40 min), the media 
were aspirated and removed. After 80 min of such pre-
incubation, which is necessary for stabilisation of AVP 
and OT release [11], explants were incubated for 20 min 
in 1 mL of nKRF {fluid B1} and then, for the next 20 
min, in 1 mL of KRF supplemented with the studied 
substance(s) or their vehicle {fluid B2}.
Series I
The aim of the first series was to examine the effect of 
different concentrations of melatonin on AVP and OT 
release from isolated rat hypothalamo-neurohypophy-
sial (H-NH) system. Explants were therefore incubated 
successively in: (i) nKRF {fluid B1} and (ii) nKRF alone 
(control group) or KRF enriched with melatonin vehicle 
(0.1 % ethanol; VEH group), or an appropriate concen-
tration of melatonin, i.e. 10-11, 10-9, 10-7, 10-5 or 10-3 M (n: 
number of samples per group, n = 7) {fluid B2}.
Series II
In series II, the influence of melatonin on forskolin-
induced AVP and OT release from isolated rat hypo-
thalamo-neurohypophysial (H-NH) system was tested 
in vitro. The experimental protocol was similar to that 
of series I. Therefore, after incubation in nKRF {fluid 
B1}, explants were next incubated in one of the follow-
ing media: KRF enriched with forskolin vehicle (0.1% 
DMSO) or forskolin solution at a concentration of 10-5 
M, or KRF supplemented with forskolin and melatonin 
with an appropriate concentration, i.e. 10-11, 10-9, 10-7, 
10-5 or 10-3 M (n = 8) {fluid B2}.
In both series, directly after each incubation period, 
the media (i.e. fluids B1 and B2) were aspirated, imme-
diately frozen and stored at –20°C until AVP and OT 
estimation by radioimmunoassay (RIA).
To determine basal and forskolin-induced AVP and OT 
secretion in vitro, the B2/B1 ratio was calculated for each 
H-NH explant. The results are expressed as B2/B1 ratio, 
because the amount of the neurohormone released into 
the medium varies from one H-NH explant to the other.
The experimental procedures were done with the 
consent (No. 19/ŁB 516/2010) of the Local Committee 
for Animal Care.
Radioimmunoassay of AVP and OT
The AVP and OT concentrations in all samples were 
assayed in duplicate by a specific RIA described previ-
ously [19–20]. Arginine vasopressin and oxytocin were 
iodinated with 125I using the chloramine-T method. The 
final dilution of anti-AVP antibodies was 1:24,000. Cross 
reactivity for these antibodies with oxytocin was 0.016%, 
with lysine vasopressin —2.7%, and with GnRH, TRH, 
leucine enkephalin, angiotensin II and substance P — 
less than 0.002%. The lower limit of detection for the 
assay was 1.56 pg AVP per tube. The intra- and inter-
assay coefficients of variation for AVP assay were less 
than 3.5% and 6.5%, respectively. The OT antibody 
titre was 1:80,000 (final dilution), and the lower limit 
of detection was 3.12 pg OT per tube. The intra- and 
inter-assay coefficients of variation for OT assay were 
less than 5.0% and 8.5%, respectively.
Statistical evaluation of the results
The neurohypophysial hormone release in vitro is finally 
expressed as a percentage of the control (Figs. 1A and 2A) 
or DMSO (Figs. 1B and 2B) value. All results are reported 
as mean ± standard error of the mean (S.E.M.). Signifi-
cance of the differences between means was evaluated 
by one-way analysis of variance (ANOVA) followed by 
Student’s t-test (for two means comparison); p < 0.05 was 
considered as the minimal level of significance.
Results
Series I
Melatonin at a concentration of 10-7 M inhibited sig-
nificantly basal AVP and OT secretion from isolated rat 
H-NH explants. When other concentrations of the hor-
mone, i.e. 10-11, 10-9 or 10-5 M, were present in the buffer, 
the AVP and OT output from the H-NH explants was 
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Figure 1. The effect of melatonin, at the concentrations of 10-11 – 10-3 M, and forskolin (Forsk.), at a concentration of 10-5 M, on basal 
(A) and forskolin-stimulated (B) vasopressin (AVP) release from the rat hypothalamo–neurohypophysial complex in vitro.
Each bar represents mean ± S.E.M.; number of samples per group (n) = 7–8; a — p < 0.05 — significantly different vs. melatonin 
vehicle (VEH) (Fig. 1A); b — p < 0.005 — significantly different vs. VEH (Fig. 1A) or Forsk. (Fig. 1B); c — p < 0.0005 -— significantly 
different vs. Forsk. (Fig. 1B)
Rycina 1. Wpływ melatoniny, w stężeniach 10-11 – 10-3 M, i forskoliny (Forsk.), w stężeniu 10-5 M, na podstawowe (A) i pobudzane 
forskoliną (B) uwalnianie wazopresyny (AVP) z układu podwzgórze–część nerwowa przysadki szczura in vitro. 
Wyniki przedstawiają średnią ± S.E.M.; liczba próbek w grupie (n) = 7–8; a — p < 0.05 — różnica istotna statystycznie względem 
VEH (ryc. 1A); b — p < 0.005 — różnica istotna względem VEH (ryc. 1A) lub Forsk. (ryc. 1B); c — p < 0.0005 — różnica istotna 
względem Forsk. (ryc. 1B)
Figure 2. The effect of melatonin, at the concentrations of 10-11–10-3 M, and forskolin (Forsk.), at a concentration of 10-5 M, on basal 
(A) and forskolin-stimulated (B) oxytocin (OT) release from the rat hypothalamo–neurohypophysial complex in vitro. 
Each bar represents mean ± S.E.M.; number of samples per group (n) = 7–8; a — p < 0.05 — significantly different vs. melatonin 
vehicle (VEH) (Fig. 2A) or Forsk. (Fig. 2B); b — p < 0.01 — significantly different vs. Forsk. (Fig. 2B); c — p < 0.005 — significantly 
different vs. VEH (Fig. 2A) or Forsk. (Fig. 2B) 
Rycina 2. Wpływ melatoniny, w stężeniach 10-11–10-3 M, i forskoliny (Forsk.), w stężeniu 10-5 M, na podstawowe (A) i pobudzane 
forskoliną (B) uwalnianie oksytocyny (OT) z układu podwzgórze–część nerwowa przysadki szczura in vitro.
Wyniki przedstawiają średnią ± S.E.M.; liczba próbek w grupie (n) = 7–8; a — p < 0.05 — różnica istotna statystycznie względem 
VEH (ryc. 2A) lub Forsk. (ryc. 2B); b — p < 0.01 — różnica istotna względem Forsk. (ryc. 2B); c — p < 0.005 — różnica istotna 
względem VEH (ryc. 2A) lub Forsk. (ryc. 2B)
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not different from the control. However, melatonin at a 
concentration of 10-3 M significantly increased both AVP 
and OT basal release into the medium (Figs. 1A and 2A).
Series II
Forskolin, at a concentration of 10-5 M, significantly 
stimulated both AVP (Fig. 1B) and OT (Fig. 2B) secre-
tion into the medium. Melatonin at the concentrations 
of 10-9, 10-7 and 10-5 M was able to reduce the forskolin-
stimulated AVP and OT secretion (the strongest effect 
was exerted by the hormone at a concentration of 10-7 
M). However, when melatonin was added to the me-
dium at a concentration of 10-3 M, it remained inactive 
in modifying the forskolin-induced AVP (Fig. 1B) and 
OT (Fig. 2B) output from the H-NH system in vitro.
Discussion
Previous experiments in vitro have shown that the 
action of melatonin on AVP and OT release from the 
rat hypothalamic explants depends not only on a con-
centration of the hormone, but also on the time of day. 
Melatonin inhibited AVP and OT secretion when the 
hypothalamic tissue was obtained from animals in light 
conditions (i.e. about 3 h after lights on), but no effect of 
the hormone could be seen when tissue samples were 
obtained during the night, i.e. 4–5 h after lights off [12]. 
Our present experiments were, therefore, performed 
during the light period of the light/dark cycle (at a time 
when the hypothalamus was found to be responsive 
to melatonin), i.e. about 4 h after lights on, and the 
results confirmed partly previous observations. We 
have shown that melatonin, at a concentration of 10-7 
M, is able to inhibit basal AVP (Fig. 1A) and OT (Fig. 2A) 
release from the H-NH system, which accords with pre-
vious results obtained when rat hypothalamus [11] or 
hamster neurointermediate lobe [13] were incubated in 
vitro. Melatonin, at a concentration of 10-11 M, remained 
inactive in influencing the AVP and OT output from 
isolated rat H-NH complex (Fig. 1A and 2A) or rat hy-
pothalamus [11], but when hamster neurointermediate 
lobe was incubated in vitro, the three concentrations of 
melatonin (10-11, 10-9 and 10-7 M) induced inhibitory ef-
fects of similar magnitude on OT and AVP release [13]. 
What is more, the highest concentration of melatonin 
used in our present experiments, i.e. 10-3 M, significantly 
stimulated basal AVP and OT release from the rat H-NH 
(Fig. 1A and 2A), which is compatible with the previous 
findings of Lemay et al. [9] and Juszczak et al. [10], but 
in conflict with the results of Yasin et al. [11], who have 
shown the inhibitory influence of 10-3 M melatonin on 
AVP and OT output from the rat hypothalamus in vitro. 
The observed discrepancies may result from the fact 
that for the present in vitro experiments we used the 
explants which contained intact neuronal projections 
from the hypothalamic SON and PVN nuclei to the neu-
rohypophysis, i.e. intact axons of the oxytocinergic and 
vasopressinergic neurones, while in the other studies 
only isolated hypothalamus [11] or neurohypophysis 
[9, 13] were incubated in vitro.
The obtained data provides further evidence in 
favour of the idea that melatonin influences the neu-
rohypophysial hormone secretion through a cAMP-
dependent mechanism. Cyclic AMP seems to be the 
main intracellular second messenger for melatonin, 
although it can also modify intracellular concentration 
of cGMP and phosphoinositide signal transduction 
cascades [14–16, 21]. Melatonin has been found to in-
hibit the enhancement of cAMP concentration evoked 
by forskolin-induced increase of AC activity in the rat 
pars tuberalis of the pituitary [14]. In several studies, 
forskolin has been found to be able to increase intracel-
lular cAMP accumulation at the concentrations of 10-4 to 
10-6 M [14–16, 21]. Therefore, for the present experiment, 
forskolin was employed at a concentration of 10-5 M, 
and we found that it stimulated significantly both AVP 
(Fig. 1B) and OT (Fig. 2B) release into the medium. To-
gether with the findings that forskolin increases cAMP 
accumulation in the rat hypothalamo-neurohypophy-
sial system in vitro [17] and cAMP stimulates both AVP 
and OT release [18], our results suggest that, under 
present experimental conditions, forskolin stimulates 
the neurohypophysial hormone release acting via 
a cAMP-dependent mechanism.
Forskolin has been described as increasing the 
cAMP accumulation in the pituitary cells after 30 min 
of incubation, which was inhibited by melatonin in 
a dose-dependent (10-10 to 10-7 M) manner [15]. Under 
present experimental conditions, we incubated the 
H-NH system for 20 min in the presence of forskolin 
and/or melatonin, and the three concentrations of mela-
tonin (10-9, 10-7 and 10-5 M) significantly diminished the 
forskolin-induced AVP and OT release, with maximal 
inhibition produced by melatonin at a concentration of 
10-7 M (Figs. 1B and 2B), which is compatible with the 
previous findings. 
On the other hand, the addition of melatonin at 
a concentration of 10-3 M to the medium containing 
forskolin did not further alter the forskolin-stimu-
lated AVP and OT release into the medium (Figs. 1B 
and 2B). Therefore, since such a high concentration 
of melatonin did not further modify significantly the 
stimulatory influence of forskolin on the neurohypo-
physial hormones release, this could imply a role for 
other intracellular mechanisms (e.g. calcium ions or 
nuclear receptors) responsible for 10-3 M melatonin-
dependent AVP and OT secretion from the rat H-NH 
system. Indeed, melatonin may easily cross cellular 
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membranes and act directly on the genome through 
nuclear orphan RZR/ROR receptors [22–23]. Numer-
ous studies on the actions of melatonin have reported 
opposite effects of so-called pharmacological (above 
1 μM) or supraphysiological (1 nM – 1 μM) and physi-
ological (below 1 nM) doses of the hormone [24], but 
it is difficult to determine which actions are mediated 
through G protein-coupled melatonin receptors, and 
which are mediated through membrane receptors-
independent mechanisms.
The possible mechanism by which melatonin 
can modify the vasopressinergic and oxytocinergic 
neurones activity includes specific G protein-coupled 
membrane receptors, called MT1 and MT2, activation 
of which inhibits the synthesis of cAMP [21, 24]. These 
receptors are situated mainly in the pars tuberalis of the 
pituitary [25] and in the hypothalamic suprachiasmatic 
(SCN) [15, 26–28] as well as magnocellular SON and 
PVN nuclei [29]. It has been found that AVP-containing 
cells in the SCN express both MT1 [27] and MT2 [28] 
melatonin receptors and melatonin inhibits AVP release 
from cultured SCN neurones [15, 28]. Moreover, it has 
been found that the cAMP-dependent pathways are 
involved in an increase in AVP gene expression in the 
SCN [30]. Thanks to the presence of MT1 and MT2 re-
ceptors, the SCN neurones could respond to melatonin 
signal [5] and then transmit it to PVN [31] and/or SON 
[32], via excitatory (glutamate) or inhibitory (GABA) 
amino acids, which are known to modify AVP and 
OT secretion in the rat [33]. Moreover, the interaction 
of melatonin with its receptors present in other brain 
regions cannot be excluded. Namely, a small amount of 
MT1 receptors has been observed in human posterior 
pituitary [29], which may suggest that melatonin exerts 
its influence on the AVP/OT release acting not only at 
the level of the hypothalamus, but also directly on the 
axonal endings located in the neurohypophysis. The 
anatomical basis for such a hypothesis is not only the 
existence of direct neuronal projection from the SCN 
to PVN and SON, but also the fact that the explant we 
used for the present in vitro experiments contained the 
whole hypothalamo-neurohypophysial system.
Melatonin may, therefore, affect the vasopressiner-
gic and oxytocinergic neurones activity and secretion 
of AVP and OT by acting directly on specific membrane 
receptors and/or nuclear orphan receptors, or it may act 
indirectly via modification of the metabolism of certain 
neuromediators/neuromodulators in the hypothalamus 
and/or in the neurointermediate lobe [34–35]. Indeed, 
melatonin has been found to have an enhancing effect 
on the GABA system [36] and to affect the activity of 
tyrosine hydroxylase in different brain regions [37], 
whereas acetylcholine, dopamine and prostaglandins 
have been found to participate in an inhibitory influ-
ence of melatonin on neurohypophysial hormone 
release from the rat hypothalamus in vitro [38]. The 
above mentioned neurotransmitters (as well as vari-
ous neurohormones and neuropeptides present in the 
central nervous system) and other numerous agents 
(e.g. biogenic amines, excitatory and inhibitory amino 
acids, nitric oxide, neurosteroids, opioids, etc.), have 
been shown to influence the activity of hypothalamic 
SON and PVN nuclei and modify the synthesis and 
release of both neurohypophysial hormones [19–20, 
33–35, 39–43], so certain combinations of these agents 
may be of some importance for the mechanisms by 
which vasopressinergic and oxytocinergic neurones 
are influenced by melatonin.
In summary, this paper demonstrates that me-
latonin significantly reduces the in vitro response 
of vasopressinergic and oxytocinergic neurones to 
forskolin, suggesting that such an effect of melatonin 
is mediated through a cAMP-dependent mechanism. 
However, the intracellular mechanism of melatonin 
action involves other possibilities, especially when 
a very high concentration (i.e. 10-3 M) of the hormone 
is considered. 
The present study provides further evidence that 
melatonin, apart from its well known action under 
the conditions of health and disease [44–45], also plays 
a role in the regulation of AVP and OT secretion from 
the rat hypothalamo-neurohypophysial system and, in 
this way, may indirectly influence water balance of the 
organism and brain function.
Conclusions
Our present results demonstrate that in the male rat: 
1. The influence of melatonin on the vasopressinergic 
and oxytocinergic neurones activity is mediated 
partly through a cAMP-dependent mechanism.
2. the effect of melatonin in this respect depends on 
its concentration.
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